21st Sep 2026 14:31
(Alliance News) - Verici Dx PLC on Monday announced the launch of TranscripTx, a genetic test designed for transplant patients, in the last quarter of the year.
However, Verici shares were down 7.6% at 0.21 pence on Monday afternoon in London. This continues the long term depreciation of the stock which lost 69% of its value in the last year.
Verici is a Cardiff, Wales-based developer of advanced clinical diagnostics for organ transplants.
The company said TranscripTx uses sequencing to identify genetic variations known to impact transplants in a patients ribonucleic acid. The test uses artificial intelligence to select genes.
Awareness about genetic variations allows physicians to understand how transplant recipients may respond to therapy and assess their long-term risk of graft failure.
By Camilla Borri, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Verici Dx